Advanced Oncotherapy Plc Successful testing supporting the superior clinical outcomes of LIGHT

Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, provided today the following technological update.

The LIGHT system has been designed to electronically control the fast delivery of protons to the tumour site. This unique ability provides the opportunity to alter the exact amount of radiation that is given to every part of the tumour in a few micro-seconds. This feature is invaluable for accurate tumour targeting and side-effect minimisation, particularly in the case of moving targets. As part of its testing and regulatory plan, the Company has developed a Time-of-Flight (“TOF”) measurement system which measures the speed of the beam; this allows the system to measure the energy of each proton pulse, which is a very important clinical parameter.

TOF testing of beam energy control and adjustment has proved to be successful with real-time results demonstrating remarkably good agreement with computer simulations. The accurate evaluation of the beam energy requires measurement of time differences to picosecond precision (a picosecond being the time it takes light to travel one third of a millimetre).

In the meantime, the Company continues to make significant progress with power testing of the Side Coupled Drift Tube Linac (“SCDTL”) integrated with the Radiofrequency Quadrupole (“RFQ”) and proton source. With much of the technological development now de-risked, the Company is on target to have a system capable of treating superficial tumours by the end of Q3 2018.

Jonathan Farr, Director of Medical Physics at Advanced Oncotherapy Plc, said: “Proton therapy is a high precision patient treatment. In proton therapy, the beam energy determines the depth of dose deposition in the patient. Because of the protons stopping in the patient’s body during treatment, we would like to know the proton beam energy at the instant it is delivered. The new Advanced Oncotherapy Time-of-Flight on-line energy measurement feature gives us the ability to do just that. I consider it to be a real advancement from previous and existing systems on the market and a key building block in offering more versatile treatments with the potential for significantly improved clinical outcomes.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Advanced Oncotherapy Plc

    More articles like this

    Hardman & Co

    Advanced Oncotherapy: Understanding the significance of 230MeV

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology, developed originally at the world-renowned CERN. The complex assembly of the first LIGHT accelerator in Daresbury

    Hardman & Co

    Advanced Oncotherapy: Major milestone achieved

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology, developed originally at the world-renowned CERN. The complex assembly of its first LIGHT accelerator in Daresbury

    Hardman & Co

    Advanced Oncotherapy: LIGHT – regulatory update

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. The company is in the process of completing the complex

    Hardman & Co

    Advanced Oncotherapy: On the home straight

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly

    Hardman & Co

    Advanced Oncotherapy: Funded to completion

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly

    Hardman & Co

    Advanced Oncotherapy: Leveraging the modularity of LIGHT

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly

    Hardman & Co

    Advanced Oncotherapy funded through to clinical events

    AVO’s goal is to deliver an affordable and novel proton therapy (PT) system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, the project has been significantly de-risked

    Hardman & Co

    Advanced Oncotherapy Rapidly changing to commercial execution

    Advanced Oncotherapy plc (LON:AVO) is the topic of discussion when Dr Martin Hall Analyst at Hardman & Co joins DirectorsTalk. Martin talks us through the interesting developments being made at the company, commercial deals, brings us up

    Hardman & Co

    Advanced Oncotherapy Confidence in LIGHT gaining momentum

    The Advanced Oncotherapy PLC (LON:AVO) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In the past 18 months, the project has

    Hardman & Co

    Why is Advanced Oncotherapy well positioned for the future?

    Advanced Oncotherapy plc (LON:AVO) is the topic of conversation when Dr Martin Hall, Head of Life Sciences at Hardman & Co joins DirectorsTalk. Martin talks us through some interesting developments at the company, explains what has

    Hardman & Co

    Advanced Oncotherapy FLASH benefits from new US reimbursement

    Advanced Oncotherapy‘s (LON:ONC) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In the past 18 months, the project has been de-risked